Tensha Therapeutics

Tensha Therapeutics

Small molecule selective bromodomain inhibitors for treating cancer and other diseases. Learn more
  • Edit
DateInvestorsAmountRound

$15.0m

Series A
N/A

N/A

Early VC

$535m

Valuation: $535m

Acquisition
Total Funding€13.6m

Recent News about Tensha Therapeutics

Edit
More about Tensha Therapeuticsinfo icon
Edit

Tensha Therapeutics is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in oncology and rare diseases. The company operates in the highly specialized field of drug development, targeting specific patient populations with limited treatment options. Tensha Therapeutics employs a business model centered around research and development (R&D), leveraging cutting-edge science to create novel therapeutic solutions. The company generates revenue through partnerships, licensing agreements, and eventual commercialization of its proprietary drugs. Tensha Therapeutics serves a global market, primarily collaborating with healthcare providers, research institutions, and pharmaceutical companies. By focusing on niche markets with high medical needs, the company aims to bring transformative treatments to patients, thereby improving their quality of life.

Keywords: biopharmaceutical, oncology, rare diseases, drug development, R&D, partnerships, licensing, commercialization, healthcare, transformative treatments.